Radiopharmaceuticals for pretargeted PET imaging beyond the barriers (PET Barrier)

Description of the granted funding

Positron emission tomography (PET) is an essential method in clinical diagnostics and in drug discovery and development. Nanomedicines and antibody-based therapies are emerging technologies in drug development for treating cancer and neurodegenerative diseases. Nanomedicines and antibodies have typically slow pharmacokinetics, which necessitates use of long living radioisotopes for tracing their distribution with PET. This causes unnecessary radiation burden. The main objective of the project is to develop PET radiopharmaceuticals, which allow pretargeted PET imaging of nanomedicines and antibodies by using short living positron emitters and with lower radiation dose. The developed diagnostics methods will advance development of therapies against cancer and neurodegenerative diseases and can later be utilized in patient stratification for identifying the patients that are most likely to benefit from the therapy.
Show more

Starting year

2021

End year

2025

Granted funding

Anu Airaksinen Orcid -palvelun logo
600 000 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

343608

Fields of science

Chemical sciences

Research fields

Kemia

Identified topics

pharmacy, biomedicine